T0	Participants 87 111	Guillian-Barre syndrome.
T1	Participants 183 276	plasma exchange (PE) and intravenous immunoglobulin (IVIg) for Guillian-Barre Syndrome (GBS).
T2	Participants 294 380	64 adult patients with GBS for PE and IVIg treatment, respectively, and nerve function
T3	Participants 846 870	reduce the GBS patients'
T4	Participants 1310 1336	rehabilitation of patients